CRNX•Vertex Pharmaceuticals will acquire Crinetics in a $10 billion all-cash transaction announced July 7. Crinetics shares surged 99% in intraday trading on the takeover news.
On July 7, Vertex Pharmaceuticals agreed to acquire Crinetics Therapeutics in a $10 billion all-cash transaction, valuing Crinetics at a substantial premium to its previous market capitalization.
Following the announcement, Crinetics shares soared 99% in intraday trading, while Vertex shares climbed modestly, reflecting investor confidence in the strategic expansion of Vertex’s clinical pipeline.
